Author

Adam Elhofy

OpenAlex ID: A5010494124

Tolerogenic Immune Modifying Nanoparticles (TIMP) Encapsulating Multiple Diabetogenic Epitopes Prevent Onset of Type 1 Diabetes in NOD Mice

2022 · Samantha Genardi, Joseph R Podojil, et al. · The Journal of Immunology · 1

Therapeutic treatment with a single CD4+ T cell epitope containing PLGA nanoparticles reverses CD8+ T Cell induced Type I Diabetes 2260609

2026 · Andrew Cogswell, Tobias Neef, et al. · The Journal of Immunology

Therapeutic antigen-specific PLGA nanoparticles tolerance induces detectable changes in the spleen, blood, and disease-associate tissue 2260904

2026 · Joseph Podojil, Andrew Cogswell, et al. · The Journal of Immunology

Tu2019 CNP-104 DEMONSTRATES ANTIGEN-SPECIFIC IMMUNE TOLERANCE IN PBC VIA PATHOGENIC CYTOKINE REDUCTION AND TOLEROGENIC T CELL EXPANSION

2026 · Adam Elhofy, Christopher L. Bowlus, et al. · Gastrointestinal Endoscopy

Tu2019 CNP-104 DEMONSTRATES ANTIGEN-SPECIFIC IMMUNE TOLERANCE IN PBC VIA PATHOGENIC CYTOKINE REDUCTION AND TOLEROGENIC T CELL EXPANSION

2026 · Adam Elhofy, Christopher L. Bowlus, et al. · Gastroenterology

Tu2020 CNP-104, AN INVESTIGATIONAL ANTIGEN-SPECIFIC NANOPARTICLE THERAPY, DEMONSTRATES FAVORABLE SAFETY AND EARLY SIGNAL OF DISEASE STABILIZATION IN A PHASE 2A RANDOMIZED, PLACEBO- CONTROLLED TRIAL IN PATIENTS WITH PBC, SUPPORTING ADVANCEMENT TO NEXT PHASE TRIALS

2026 · Christopher L. Bowlus, Adam Elhofy, et al. · Gastrointestinal Endoscopy

Tu2020 CNP-104, AN INVESTIGATIONAL ANTIGEN-SPECIFIC NANOPARTICLE THERAPY, DEMONSTRATES FAVORABLE SAFETY AND EARLY SIGNAL OF DISEASE STABILIZATION IN A PHASE 2A RANDOMIZED, PLACEBO- CONTROLLED TRIAL IN PATIENTS WITH PBC, SUPPORTING ADVANCEMENT TO NEXT PHASE TRIALS

2026 · Christopher L. Bowlus, Adam Elhofy, et al. · Gastroenterology

OS-089 CNP-104, an investigational antigen-specific therapy, demonstrates favorable impact across multiple analyses of liver stiffness measurement in a Phase 2a randomized, placebocontrolled trial in PBC

2026 · Christopher L. Bowlus, Adam Elhofy, et al. · Journal of Hepatology

SAT-282 CNP-104, an investigational antigen-specific therapy, demonstrates evidence of improved hepatic function and prognostic risk in a phase 2a randomized, placebo-controlled trial in PBC

2026 · Christopher L. Bowlus, Adam Elhofy, et al. · Journal of Hepatology

Therapeutic treatment with PLGA nanoparticles containing a single CD4+ epitope reverses CD8+ T cell-induced type I diabetes disease progression 3303

2025 · Andrew C. Cogswell, Ming-Yi Chiang, et al. · The Journal of Immunology

Induction of Antigen-Specific T Cell Tolerance by CNP-104 Positively Affects Clinical Response in Primary Biliary Cholangitis (PBC) 9237

2025 · Adam Elhofy, Christopher Bowlus, et al. · The Journal of Immunology

STING and IFNalpha/beta receptor are required for antigen-specific apoptotic cell-induced peripheral tolerance 3152

2025 · Joseph R. Podojil, Andrew C. Cogswell, et al. · The Journal of Immunology

Antigen-specific nanoparticle tolerance reduced inflammation at the target tissue and increased target protein expression in recombinant adeno-associated virus (AAV)-mediated gene therapy

2024 · Joseph Podojil, Dan Xu, et al. · The Journal of Immunology

Antigen-specific nanoparticle tolerance treatment actively induces regulatory mechanisms via the STING pathway

2023 · Joseph R Podojil, Andrew C Cogswell, et al. · The Journal of Immunology

Antigen-specific nanoparticle tolerance treatment actively induces both FoxP3- and IL-10-dependent regulatory mechanisms

2022 · Joseph R Podojil, Andrew Cogswell, et al. · The Journal of Immunology

Nanoparticles divert monocytes away from the lungs to improve outcomes after influenza virus infection in aged mice

2022 · Adam Elhofy, William J Kelley, et al. · The Journal of Immunology

Works count: 16

Citation count: 1

H-index: 1

I10-index: